Other

Eberhard-karls-universitaet Tuebingen Universitaetsklinikum

Eberhard-karls-universität Tübingen Universitätsklinikum

Bossow, Sascha

Bitzer, Michael

Lange, Sebastian

Lampe, Johanna

Zimmermann, Martina

Berchtold, Susanne

Lauer, Ulrich M.

Neubert, Wolfgang J.

Michael Bitzer

Sascha Bossow

Wolfgang J Neubert

Ulrich Manfred Lauer

Sebastian Lange

Martina Zimmermann

Susanne Berchtold

Johanna Lampe

Sorin Armeanu-Ebinger

Martina Schell

Ulrich M Lauer

Wolfgang Neubert

The present invention relates to a genetically modified Paramyxovirus, a pharmaceutical composition comprising this paramyxovirus, the use of a genetically modified Paramyxovirus for the therapeutic and/or prophylactic treatment of a tumor disease, and a method for the production of a pharmaceutical composition for the therapeutic or prophylactic treatment of a tumor disease.

Genetically modified paramyxovirus for treatment of tumor diseases

The present invention pertains to a pharmaceutical composition comprising a recombinant measles virus encoding a suicide gene for use in the treatment of malignant cells with primary or secondary resistances against an oncolytic measles virus without suicide gene activity. Further, the present invention pertains to a recombinant measles virus based on measles vaccine strain Schwarz encoding a suicide gene, which comprises a fusion of a cytosine deaminase, particularly yeast cytosine deaminase, and a uracil phosphoribosyltransferase, particularly yeast uracil phosphoribosyltransferase, to a method and a kit for preparing the recombinant measles virus as claimed herein.

Oncolytic measles virus

Growing community of inventors

Rottenburg, Germany

Michael Bitzer